
    
      Subjects will receive treatment with pazopanib at a dose of 800 mg orally once daily.
      [18F]Fluciclatide imagings will be taken 2 times; 1) before systemic therapy (at baseline),
      2) at one week after starting of Pazopanib. However, If the target lesion on the baseline PET
      cannot be discriminated compared to the background activity, the 2nd PET will not be done.
      Response evaluation by CT will be performed at baseline, at 6 week, at 12 week and every 8
      weeks thereafter until the end of treatment. RECIST1.1 criteria for response will be applied.
      Patient will be treated with Pazopanib until there is disease progression, unacceptable
      toxicity or withdrawal of patient consent.
    
  